ReviewFrontiers in immunology2022
The Effect of Hypoxia-Induced Exosomes on Anti-Tumor Immunity and Its Implication for Immunotherapy.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 33 citations in OpenAlex.
- CCL26-Mediated Modulation of Endothelial Secretome by Hypoxia-Induced Tumor-Derived Exosomes Enhances Metastatic Progression in Head and Neck Cancer.Head & neck · 2026Article
- Hippo Pathway Regulation and Microenvironmental Cues Governing Human MSC Transition to Cancer-Associated Fibroblasts.Journal of cellular physiology · 2026Article
- Visualizing extracellular vesicles in cancer: from biogenesis to theranostic applications.Journal of nanobiotechnology · 2026Review
- Hybrid exosomes: a rising horizon for precision cancer therapy.RSC advances · 2026Review
- Characterization of exosomes from hypoxia-activated human amniotic membrane mesenchymal stem cells.Iranian journal of basic medical sciences · 2026Article
- Hypoxic Endothelial-Cell-Derived Exosomal lnc-DKK3 Reprograms Tumor-Associated Macrophages via USP47/PD-L1/RelA Axis to Promote Glioma Progression.Research (Washington, D.C.) · 2026Article
- Review
- Dendritic Cell-Derived Exosomes: Next Generation of Cancer Immunotherapy.Biomedicines · 2025Review
- The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma.Investigational new drugs · 2025Review
- FKBP prolyl isomerase 4: a potential target for heart failure and cardioprotective effects via leonurine-pretreated mesenchymal stem cell-derived exosomes.Stem cell research & therapy · 2025Article
- Hypoxic exosomes alleviated the spinal cord injury after ischemic/reperfusion in a rat model.Advanced pharmaceutical bulletin · 2025Article
- Pathways and outputs orchestrated in tumor microenvironment cells by hypoxia-induced tumor-derived exosomes in pan-cancer.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Exosome-based cancer vaccine: a cell-free approach.Molecular biology reports · 2025Review
- Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics.Cancers · 2025Review
- Exosomes play a crucial role in remodeling the tumor microenvironment and in the treatment of gastric cancer.Cell communication and signaling : CCS · 2025Review
- Hypoxic BMSC-derived exosomal miR-210-3p promotes progression of triple-negative breast cancer cells via NFIX-Wnt/β-catenin signaling axis.Journal of translational medicine · 2025Article
- Exosome miRNA sorting controlled by RNA-binding protein-motif interactions.Extracellular vesicles and circulating nucleic acids · 2025Review
- From biomolecules to breakthroughs: exosomes as next-generation theranostics in female infertility.Frontiers in cell and developmental biology · 2025Review
- Known and unknown: Exosome secretion in tumor microenvironment needs more exploration.Genes & diseases · 2025Review
- Functions and Clinical Applications of Exosomes in Gastric Cancer.International journal of biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a critical feature of solid tumors and is considered to be a key factor in promoting tumorigenesis and progression. Beyond inducing metabolic reprogramming of tumor cells to adapt to the hypoxia tumor microenvironment (TME), hypoxia can also promote tumor growth by affecting the secretion of exosomes. Exosomes are nano-sized (30-150 nm in diameter) extracellular vesicles that can carry numerous substances including lipids, proteins, nucleic acids, and metabolites. Notably, hypoxia-induced exosomes alterations not only exist in tumor cells, but also in various TME cells including stromal cells and immune cells. Besides promoting tumor invasion, angiogenesis, and drug resistance, the secretion of these altered exosomes has recently been found to negatively regulate anti-tumor immune responses. In this review, we focus on the hypoxia-induced changes in exosome secretion and found it can contributes to immune evasion and cancer progression by recruiting protumor immune cells into TME, as well as inhibiting antitumor immune cells. Next, we also describe the recent advances of exosomes in immunotherapy and future direction. In conclusion, ongoing discoveries in this field have brought new insights into hypoxia exosome-led immunosuppression, enabling the development of exosome-based therapeutics and elucidating their potential in immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.